Hikma Pharmaceuticals Shares Outstanding vs. Current Asset
| HKMPY Stock | USD 50.14 1.56 3.21% |
For Hikma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hikma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hikma Pharmaceuticals PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hikma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hikma Pharmaceuticals PLC over time as well as its relative position and ranking within its peers.
Hikma |
Hikma Pharmaceuticals PLC Current Asset vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Hikma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hikma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Hikma Pharmaceuticals PLC is one of the top stocks in shares outstanding category among its peers. It also is one of the top stocks in current asset category among its peers fabricating about 14.23 of Current Asset per Shares Outstanding. Comparative valuation analysis is a catch-all model that can be used if you cannot value Hikma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hikma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Hikma Current Asset vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Hikma Pharmaceuticals |
| = | 110.13 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Hikma Pharmaceuticals |
| = | 1.57 B |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Hikma Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Hikma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hikma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Hikma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Hikma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.
Hikma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Hikma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hikma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hikma Pharmaceuticals' important profitability drivers and their relationship over time.
Use Hikma Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hikma Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hikma Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Hikma Pharmaceuticals Pair Trading
Hikma Pharmaceuticals PLC Pair Trading Analysis
The ability to find closely correlated positions to Hikma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hikma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hikma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hikma Pharmaceuticals PLC to buy it.
The correlation of Hikma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hikma Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hikma Pharmaceuticals PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hikma Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Hikma Pharmaceuticals position
In addition to having Hikma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.